Circio Holding ASA Stock price

Equities

TRVX

NO0013033795

Biotechnology & Medical Research

Real-time Oslo Bors 09:20:00 2024-03-27 am EDT 5-day change 1st Jan Change
6 NOK 0.00% Intraday chart for Circio Holding ASA +0.84% -16.67%
Sales 2023 * - Sales 2024 * 200M 18.42M Capitalization 45.69M 4.21M
Net income 2023 * -102M -9.39M Net income 2024 * 7M 645K EV / Sales 2023 * -
Net cash position 2023 * 23.58M 2.17M Net cash position 2024 * 169M 15.56M EV / Sales 2024 * -0.62 x
P/E ratio 2023 *
-0.57 x
P/E ratio 2024 *
1.03 x
Employees 17
Yield 2023 *
-
Yield 2024 *
-
Free-Float 81.31%
More Fundamentals * Assessed data
Dynamic Chart
Circio Partner Exercises Option to License Cancer Vaccine in China MT
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China CI
Atlas Special Opportunities Converts Circio's Convertible Bonds to Shares MT
Circio Doses First Patient in Phase 2 Trial of Cancer Vaccine MT
Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University CI
Circio Gets Approval for EUR6 Million Loans Waiver for Tumor Cell Technology Development MT
Circio Holding Asa Receives Waiver of Eur 6.2 Million in Loans from Business Finland CI
Atlas Special Opportunities Converts NOK1 Million of Circio Convertible Bonds MT
Circio Partner Files Investigational New Drug Application for Cancer Vaccine in China MT
IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration CI
Circio to Begin Clinical Trial for Blood Cancer Vaccine After Successful Safety Review MT
Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital CI
Transcript : Circio Holding ASA - Special Call
Circio Joins Collaboration to Test the Combination of TG01 Vaccination with Daratumumab and Nivolumab in Immunotherapy-Resistant Patients with Mutant RAS Cancers CI
Georgetown University-led Collaboration to Test Circio's Drug Candidate Against RAS-mutated Cancers MT
More news

Latest transcript on Circio Holding ASA

1 week+0.84%
Current month-4.00%
3 months-18.48%
6 months-45.95%
Current year-16.67%
More quotes
1 week
5.70
Extreme 5.7
6.30
1 month
5.62
Extreme 5.62
8.00
Current year
5.62
Extreme 5.62
8.10
1 year
5.62
Extreme 5.62
23.97
3 years
5.62
Extreme 5.62
288.00
5 years
5.62
Extreme 5.62
360.00
10 years
5.62
Extreme 5.62
1 080.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-03-31
Director of Finance/CFO 56 22-03-06
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 64 15-09-13
Director/Board Member 58 22-04-20
Director/Board Member 77 15-06-30
More insiders
Date Price Change Volume
24-03-27 6 0.00% 32,901
24-03-26 6 +0.02% 25,026
24-03-25 5.999 -7.57% 45,448
24-03-22 6.49 +9.08% 65,806
24-03-21 5.95 -4.03% 100,678

Real-time Oslo Bors, March 27, 2024 at 09:20 am EDT

More quotes
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio's second clinical program is an immunotherapy targeting KRAS driver mutations.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6 NOK
Average target price
48 NOK
Spread / Average Target
+700.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Circio Holding ASA - Oslo Bors